Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI